ArticlePeerJ2017
Mechanisms of action and
Article in PeerJ, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Enhanced antibacterial activity of antimicrobial peptide-antibiotic combinations against multidrug-resistant bacteria.FEMS microbes · 2026Review
- Dual Core-Shell Loaded Lipid-Polymer Hybrid Nanoparticles as Combination Anti-Infective Delivery Platforms.Pharmaceutics · 2025Article
- A Potent Antibacterial Peptide (P6) from the De Novo Transcriptome of the MicroalgaInternational journal of molecular sciences · 2024Article
- Indolicidin revisited: biological activity, potential applications and perspectives of an antimicrobial peptide not yet fully explored.World journal of microbiology & biotechnology · 2022Review
- Influence of the Polysaccharide Capsule on the Bactericidal Activity of Indolicidin on SFrontiers in microbiology · 2022Article
- Antimicrobial Peptides and Proteins: From Nature's Reservoir to the Laboratory and Beyond.Frontiers in chemistry · 2021Review
- Application of multi-omics technology for the elucidation of anti-pneumococcal activity of 3-acyl-2-phenylamino-1,4-dihydroquinolin-4-one (APDQ) derivative against Streptococcus pneumoniae.Scientific reports · 2020Article
- Isolation of Antimicrobial Genes fromInternational journal of molecular sciences · 2020Article
- Synergistic Effect of a Pleuromutilin Derivative with Tetracycline againstMolecules (Basel, Switzerland) · 2020Article
- Article
- Hybrids made from antimicrobial peptides with different mechanisms of action show enhanced membrane permeabilization.Biochimica et biophysica acta. Biomembranes · 2019Article
- Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance?Frontiers in cellular and infection microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial peptides (AMPs) are of great potential as novel antibiotics for the treatment of broad spectrum of pathogenic microorganisms including resistant bacteria. In this study, the mechanisms of action and the therapeutic efficacy of the hybrid peptides were examined.
methodsTEM, SEM and ATP efflux assay were used to evaluate the effect of hybrid peptides on the integrity of the pneumococcal cell wall/membrane. DNA retardation assay was assessed to measure the impact of hybrid peptides on the migration of genomic DNA through the agarose gel.
resultsThe results obtained from TEM and SEM indicated that the hybrid peptides caused significant morphological alterations in DISCUSSION: Our results suggest that attacking and breaching the cell wall/membrane is most probably the principal mechanism for the hybrid peptides. In addition, the hybrid peptides could possess another mechanism of action by inhibiting intracellular functions such as DNA synthesis. AMPs could play a great role in combating antibiotic resistance as they can reduce the therapeutic concentrations of standard drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.